Trials / Active Not Recruiting
Active Not RecruitingNCT06716424
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
Detailed description
The study duration will be up to 27 weeks, with a treatment duration approximately 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iGlarLixi (insulin glargine/lixisenatide) | iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously |
Timeline
- Start date
- 2025-01-06
- Primary completion
- 2026-06-26
- Completion
- 2026-06-26
- First posted
- 2024-12-04
- Last updated
- 2026-04-08
Locations
10 sites across 1 country: India
Source: ClinicalTrials.gov record NCT06716424. Inclusion in this directory is not an endorsement.